Given the substantial body of evidence supporting the involvement of STMN1 in oncogenesis, not only in hematological cancers but also in various solid tumors [54,55], selective STMN1 inhibitors have yet to be developed and could pave the way for significant advances in antineoplastic therapy. Here, STMN1 is linked to hematopoietic and lymphoid cell neoplasm.